In these analyses of tumor tissue from patients enrolled in the open-label, Phase 2 ABRAZO study, 97% of evaluable tumors exhibited ≥1 BRCA1/2mut and there was 95% concordance between known gBRCA1/2mut and tBRCA1/2mut; this is perhaps unsurprising given the importance of gBRCAmut in breast cancer pathology, and the fact that patients were selected based on gBRCAmut status. This evidence concerns the gene BRCA1 and neoplasm.